Nevertheless, it remains uncertain whether HER2 signaling affects the effectiveness of CDK4/6 inhibitor administered in combination with endocrine therapy for HR+/HER2-low breast cancer and suitable intervention measures. The gene discussed is ERBB2; the disease is breast carcinoma.